Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615712 · ClinicalTrials.gov registry record
PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study
A clinical trial, sponsored by CorEvitas.
- Recruiting
- Registry status
- 2,500
- Enrollment target
NCT07615712: Recruiting study, sponsored by CorEvitas.
NCT07615712 is a clinical trial that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07615712 is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
This is a 16-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 2 (+/- 5 days), 4 (+/- 5 days), and 16 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 2, Week 4, and Week 16) using a structured and standardized data collection tool.
Primary Outcome
Creation of a cohort of psoriasis subjects to describe the changes at 2,4, and 16 weeks after initiation of the advanced therapy.
Interventions
- OTHER Observational (Non-Interventional) Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2035-12 |
What NCT07615712 shows while recruiting
NCT07615712 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Observational (Non-Interventional) Registry is the first listed.
NCT07615712 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07615712 about?
NCT07615712 is a clinical study titled "PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study". This is a 16-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurri...
What is the current status of trial NCT07615712?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2025-04-30. Estimated completion is 2035-12.
What interventions are being tested in trial NCT07615712?
The interventions under investigation include: Observational (Non-Interventional) Registry (OTHER).
Who is sponsoring clinical trial NCT07615712?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI